Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MIST | US
-0.02
-0.99%
Healthcare
Biotechnology
30/06/2024
13/04/2026
2.00
1.99
2.07
1.90
Milestone Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil a novel and potent calcium channel blocker which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal Canada.
View LessValue Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
104.8%1 month
146.8%3 months
91.2%6 months
82.8%-
-
2.48
1.67
0.60
-1.43
81.44
-
-49.19M
106.54M
106.54M
-
-
-
-100.00
-133.75
3.33
0.83
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.17
Range1M
1.17
Range3M
1.17
Rel. volume
0.63
Price X volume
3.91M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Tiziana Life Sciences PLC | TLSA | Biotechnology | 1.15 | 116.74M | -2.54% | n/a | 0.00% |
| Elicio Therapeutics Inc. | ELTX | Biotechnology | 10.84 | 113.48M | 6.80% | 5.18 | -388.56% |
| QSI | QSI | Biotechnology | 0.7887 | 112.28M | 6.51% | n/a | 0.71% |
| Dermira Inc | DERM | Biotechnology | 5.2 | 107.78M | 0.58% | 47.08 | 201.92% |
| Aldeyra Therapeutics Inc | ALDX | Biotechnology | 1.8 | 106.96M | 1.12% | n/a | 15.90% |
| Common Stock | TARA | Biotechnology | 5.07 | 104.59M | 2.22% | n/a | 5.41% |
| Pyxis Oncology Inc. Common Stock | PYXS | Biotechnology | 1.71 | 101.61M | 0.59% | n/a | 12.29% |
| Cellectar Biosciences Inc | CLRB | Biotechnology | 2.74 | 98.23M | -0.72% | n/a | 2.10% |
| IN8bio Inc. Common Stock | INAB | Biotechnology | 1.35 | 97.94M | -2.88% | n/a | 43.30% |
| Surrozen Inc. Common Stock | SRZN | Biotechnology | 29.86 | 95.73M | 5.89% | n/a | 35.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.69 | 99.62M | -0.67% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 5.85 | 95.29M | 4.09% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.6936 | 73.22M | -0.73% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.56 | 64.29M | 0.28% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.43 | - | Cheaper |
| Ent. to Revenue | 81.44 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.48 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 91.20 | - | Riskier |
| Debt to Equity | 1.67 | -1.23 | Expensive |
| Debt to Assets | 0.60 | 0.25 | Expensive |
| Market Cap | 106.54M | - | Emerging |